Junjie Wu
Boston University
10 Papers
4 Citations
Junjie Wu is an academic researcher from Boston University. The author has contributed to research in topics: Metronomic Chemotherapy & Immunogenic cell death. The author has an hindex of 8, co-authored 9 publications.
Chat about Author
Papers
miR-29 Is a Major Regulator of Genes Associated with Pulmonary Fibrosis
Leah Cushing,Ping Ping Kuang,Jun Qian,Fengzhi Shao,Junjie Wu,Frederic F. Little,Victor J. Thannickal,Wellington V. Cardoso,Jining Lu +8 more
TL;DR: A large-scale screening for miRNAs potentially involved in bleomycin-induced fibrosis found expression of miR-29 family members significantly reduced in fibrotic lungs, and gene expression profiles of human fetal lung fibroblast IMR-90 cells in which endogenous miR -29 was knocked down strongly suggest a role of mi R-29 in the pathogenesis of pulmonary fibrosis.
Immunogenic chemotherapy: Dose and schedule dependence and combination with immunotherapy.
Junjie Wu,David J. Waxman +1 more
TL;DR: A strategy for effective immunogenic chemotherapy that employs a modified metronomic schedule for drug delivery, which is term medium-dose intermittent chemotherapy (MEDIC), where an immunogenic cancer chemotherapeutic agent is administered intermittently and at an intermediate dose, designed to impart strong and repeated cytotoxic damage to tumors, thereby maximizing anti-cancer activity.
300
Metronomic cyclophosphamide eradicates large implanted GL261 gliomas by activating antitumor Cd8+ T-cell responses and immune memory
Junjie Wu,David J. Waxman +1 more
TL;DR: Findings provide proof-of-concept that single-agent chemotherapy delivered on an optimized metronomic schedule can eradicate large, established tumors and induce long-term immune memory.
97
Metronomic cyclophosphamide activation of anti-tumor immunity: tumor model, mouse host, and drug schedule dependence of gene responses and their upstream regulators
TL;DR: These findings elucidate molecular response pathways activated by intermittent metronomic CPA treatment and identify deficiencies that characterize immune-unresponsive tumor models and drug schedules.
Delicate Balances in Cancer Chemotherapy: Modeling Immune Recruitment and Emergence of Systemic Drug Resistance.
Anh Phong Tran,M. Ali Al-Radhawi,Irina Kareva,Junjie Wu,David J. Waxman,Eduardo D. Sontag,Eduardo D. Sontag +6 more
TL;DR: A mathematical model is developed to elucidate the underlying complex interactions between tumor growth, immune system activation, and therapy-mediated immunogenic cell death and suggests that immunostimulatory and immunosuppressive intermediates are responsible for the observed phenomena of resistance and immune cell recruitment.